Structure–Activity Relationship and Pharmacokinetic Studies of Sotrastaurin (AEB071), a Promising Novel Medicine for Prevention of Graft Rejection and Treatment of Psoriasis

Jürgen Wagner(Vogtland-Klinik), Sylvain Cottens, Peter Matt(Novartis (Switzerland)), Richard Sedrani(Novartis (Switzerland)), Christian Jean(Novartis (Switzerland)), Christian Beerli(Novartis (Switzerland)), Gisbert Weckbecker(Novartis (Switzerland)), Nigel G. Cooke(Novartis (Switzerland)), Jean-Pierre Evenou(Novartis (Switzerland)), Bernard Faller(Novartis (Switzerland)), Gerhard Zenke, Rainer Albert(Novartis (Switzerland)), Hansjörg Wiegand(Novartis (Switzerland))
Journal of Medicinal Chemistry
July 28, 2011
10.1021/jm200469u
Cited by 39

Related Papers

Efficient Aldolase Catalytic Antibodies That Use the Enamine Mechanism of Natural Enzymes
|Science|1995|458
Computational approaches to determine drug solubility
|Advanced Drug Delivery Reviews|2007|169
The Potent Protein Kinase C-Selective Inhibitor AEB071 (Sotrastaurin) Represents a New Class of Immunosuppressive Agents Affecting Early T-Cell Activation
|Journal of Pharmacology and Experimental Therapeutics|2009|160
Discovery of 3-(1<i>H</i>-Indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione (AEB071), a Potent and Selective Inhibitor of Protein Kinase C Isotypes
|Journal of Medicinal Chemistry|2009|135
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C
|Cancer Discovery|2022|134